Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival

Invasion and Metastasis

Volumn 16, Issue 3, 1996, Pages 132-143

  Sciumbata, Teresa ^a   Caretto, Patrizia ^a   Pirovano, Paola ^a   Pozzi, Pietro ^a   Cremonesi, Piero ^a   Galimberti, Giorgio ^a   Leoni, Flavio ^a   Maracucci, Fabrizio ^a  

^a Italfarmaco SpA   (Italy)

Author keywords

Heparins; Lung; Melanoma; Survival

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; LUNG METASTASIS; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ANIMALS; ANTICOAGULANTS; CELL ADHESION; CELL DIVISION; CELLS, CULTURED; EPITHELIAL CELLS; EPITHELIUM; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0030428370     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Choay J, Petitou M: The chemistry of heparin: A way to understand its mode of action. Med J Aust 1986;144(suppl HS7-HS10).
2. Johnson EA, Mulloy B: The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 1976;51:119-127.
3. Tyrrell D, Kilfeather S, Page C: Therapeutic uses of heparin beyond its traditional role as anticoagulant. TIPS 1995;16:198-204.
4. Bjork I, Lindahl U: Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982;48:161-182.
5. Lopalco L, Ciccomascolo F, Lanza P, Zoppetti G, Caramazza I, Leoni F, Beretta A, Siccardi AG: Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity. AIDS Res Hum Retroviruses 1994;10:787-793.
6. Irimura T, Nakajima M, Nicolson GL: Chemically modified heparins as inhibitors of heparan sulfate specific for endo-glucuoronidase (heparanase) of metastatic melanoma cells. Biochemistry 1986;25:5322-5328.
7. Nakajima M, DeChavigny A, Johnson CE, Hamada J-I, Stein CA, Nicolson GL: Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991;266:9661-9666.
8. Parish CR, Coombe DR, Jakobsen KB, Underwood PA: Evidence that sulfated polysaccharides inhibit tumor metastasis by blocking tumor-cell-derived heparanase. Int J Cancer 1987;40:511-517.
9. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476.
10. Andriuoli G, d'Atri G, Galimberti G, Sarret M, Zoppetti G, Casu B, Naggi A, Oreste P, Torri G: Further purification of heparin reduces its bleeding effects in the mesenteric vessel of rats. Ann NY Acad Sci 1989;556:416-418.
11. Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson LA, Linker A: Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979;76:3198-3202.
12. Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, Porta R, Prino G, Torri G, Zoppetti G: Retention of antilipemic activity by non-anticoagulant periodate-oxidized heparins. Arzneimittelforschung 1986;36:637-642.
13. Haremberg J, DeVries J: Characterization of heparins by high performance size exclusion chromatography. J Chromatogr 1983;61:287-292.
14. Talmadge JE, Fidler IJ: Cancer metastasis is selective or random dependent on the tumor cell population. Nature 1982;297:593-594.
15. Hart IR: The selection and characterization of an invasive variant of B16 melanoma. Am J Pathol 1979;97:587-600.
16. Giavazzi R, Campbell DE, Jessup JM, et al: Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986;46:1928-1933.
17. Otsuka A, Hanafusa T, Miyagawa J-I, Kono N, Tarui S: Nicotinamide and 3-aminobenzamide reduce interferon-γ-induced class II MHC (HLA-DR and DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol Immunotoxicol 1991;13:263-280.
18. Wood S Jr, Holyoke ED, Yardley JH: An experimental study of the influence of adrenal steroids, growth hormone and anticoagulants on pulmonary metastasis formation in mice. Proc Am Assoc Cancer Res 1956;2:157-158.
19. Maat B: Extrapulmonary colony formation after intravenous injection of tumor cells into heparin-treated animals. Br J Cancer 1978;37:369-376.
20. Kakkar AK, Hedges AR, Williamson RCN, Kakkar W: Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol 1995;6:885-888.
21. Lawrence EA, Moore DB, Bernstein GI: The ability of the pulmonary vascular system to influence the spread of tumor emboli. J Thorac Surg 1953;26:233-240.
22. Wood S Jr, Yardley JH, Holyoke ED: The relationship between intravascular coagulation and the formation of pulmonary metastases in mice injected intravenously with tumour suspensions. Proc Am Assoc Cancer Res 1956;2:260.
23. Chew EC, Wallace AC: Demonstration of fibrin in early stages of experimental metastases. Cancer Res 1976;36:1904-1909.
24. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL: Heparan sulfate degradation: Relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983;220:611-613.
25. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fiks A, Vlodavsky I: Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by nonanticoagulant heparin species. Blood 1987;70:551-557.
26. Ishai-Michaeli R, Svahn C-M, Webwe M, Chajec-Shaul L, Korner G, Eker HR, Vlodavsky I: Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix. Biochemistry 1992;31:2080-2088.